Clinical Trial

A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to check how much LY4256984 gets into the bloodstream and how long it takes the body to eliminate it.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-08-01; most recent amendment 2026-03-05.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07100119
Lead Sponsor Eli Lilly and Company
Conditions ALS (Amyotrophic Lateral Sclerosis)
Enrollment 32 participants
Start Date 2025-08-05
Primary Completion 2027-08 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-06